Lantheus Holdings Inc Stock

$81.49

0.93% yesterday

Nasdaq, Jun 27, 10:03 pm CET

ISIN

US5165441032

Symbol

LNTH

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Lantheus Holdings Inc Stock price

$81.49

+67.48 481.66% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.75 0.93%

ISIN

US5165441032

Symbol

LNTH

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$5.6b

Enterprise Value

$5.3b

Net debt

$-371.7m

Cash

$938.5m

Shares outstanding

69.2m

Valuation (TTM | estimate)

P/E

22.95 | 11.95

P/S

3.67 | 3.51

EV/Sales

3.43 | 3.28

EV/FCF

11.13

P/B

4.84

Financial Health

Equity Ratio

54.94%

Return on Equity

28.72%

ROCE

24.91%

ROIC

30.80%

Debt/Equity

0.49

Financials (TTM | estimate)

Revenue

$1.5b | $1.6b

EBITDA

$513.1m | $681.0m

EBIT

$450.3m

Net Income

$254.3m | $471.5m

Free Cash Flow

$473.0m

Growth (TTM | estimate)

Revenue

12.53% | 4.63%

EBITDA

-4.15% | 32.70%

EBIT

-5.08%

Net Income

-44.78% | 50.92%

Free Cash Flow

130.70%

Margin (TTM | estimate)

Gross

64.04%

EBITDA

33.39% | 42.43%

EBIT

29.30%

Net

16.55% | 29.38%

Free Cash Flow

30.78%

EPS

$3.55

FCF per Share

$6.84

Short interest

17.36%

Employees

808.00

Rev per Employee

$1.90m

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Lantheus Holdings Inc Stock Analysis

Unlock Scores for Free

??

19 Analysts have issued a Lantheus Holdings Inc forecast:

17x Buy

89%

More details on Analyst Estimates Including Price Targets

19 Analysts have issued a Lantheus Holdings Inc forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Lantheus Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1,537 1,537	13% 13% 100%
- Direct Costs	553 553	12% 12% 36%
Gross Profit	984 984	13% 13% 64%
- Selling and Administrative Expenses	378 378	24% 24% 25%
- Research and Development Expense	156 156	64% 64% 10%
EBITDA	513 513	4% 4% 33%
- Depreciation and Amortization	63 63	3% 3% 4%
EBIT (Operating Income) EBIT	450 450	5% 5% 29%
Net Profit	254 254	45% 45% 17%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Lantheus Holdings Inc Stock News

Neutral

GlobeNewsWire

●

17 days ago

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nucl...

Neutral

GlobeNewsWire

●

18 days ago

Lantheus to Present at the 2025 Truist Securities MedTech Conference

BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesd...

Neutral

PRNewsWire

●

26 days ago

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

BOCA RATON, Fla. , June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp.

More Lantheus Holdings Inc News

Company Profile

Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.

Head office	United States
CEO	Brian Markison
Employees	808
Founded	1956
Website	www.lantheus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now